A Look At Minimed Group (MMED) Valuation After Recent Share Price Weakness

Event context and recent price performance

Minimed Group (MMED) has been in focus after recent share price weakness, with the stock down 3.2% over the past week and 24.2% year to date. This has prompted fresh attention on its fundamentals.

The Northridge based diabetes technology company reports annual revenue of US$2,886 and a net loss of US$211. This places its current valuation of about US$3.9b under closer scrutiny among investors.

See our latest analysis for Minimed Group.

With the latest close at US$14.01, Minimed Group’s share price return has been weak both over the past week and year to date. This suggests momentum has faded as investors reassess its loss making profile against its current US$3.9b valuation.

If Minimed’s recent pullback has you rethinking where growth in healthcare technology might come from next, it could be worth scanning other diabetes and health focused AI names through our 36 healthcare AI stocks

With shares down 24.2% year to date, trading at US$14.01 against an analyst price target of US$22.45 and an indicated intrinsic discount of about 77%, is this a reset that offers value, or is the market already baking in future growth?

Preferred price to sales multiple of 1.4x: Is it justified?

On a P/S basis, Minimed Group trades at 1.4x, which screens as good value against both peer companies on 2.1x and the wider US medical equipment group on 2.6x.

The P/S ratio compares the company’s market value to its annual revenue and is often used when a business is loss making, as is the case here. For Minimed, a $3.9b market cap against $2,886 in annual revenue produces that 1.4x figure, which sits below the reference points flagged by the data.

With Minimed still reporting a net loss of $211 alongside revenue growth and forecasts that point to the company moving into profitability over the next few years, a lower P/S can suggest the market is hesitant to fully price in that earnings shift. At the same time, the company is assessed as trading 76.7% below an internal fair value estimate and below an SWS DCF model output that places future cash flow value at $60.25 per share, compared with the current $14.01 price. In this context, the multiples view and the cash flow view both lean toward the current price being on the low side relative to those benchmarks.

Against the broader US medical equipment industry average P/S of 2.6x, Minimed’s 1.4x looks meaningfully lower and implies investors are currently assigning less value per dollar of revenue than the sector reference point. If sentiment or forecasts shift, that gap could close toward the levels suggested by the peer group or the DCF based fair value, but as always, that depends on how revenue, margins and cash generation actually play out over time.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Preferred multiple of Price to sales ratio of 1.4x (UNDERVALUED)

However, investors still need to weigh risks such as ongoing net losses of US$211m and any slowdown in revenue growth from US$2,886m, which could challenge today’s valuation.

Find out about the key risks to this Minimed Group narrative.

Another view: DCF points to a bigger gap

While the current P/S of 1.4x hints at value, our DCF model presents a different picture. It puts future cash flow value at $60.25 per share versus today’s $14.01, implying the shares trade well below that estimate. This raises the question of whether the market is being cautious or overly pessimistic.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Minimed Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 59 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on value and risk here, so if this setup interests you, consider reviewing the details promptly and forming your own view with our 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Minimed's setup has you thinking about what else might be worth your attention, now is a good time to broaden your watchlist with a few focused screens.

• Target potential mispricings by scanning companies that look cheap on quality metrics using our 59 high quality undervalued stocks.
• Prioritise strength and resilience by checking out companies highlighted in the solid balance sheet and fundamentals stocks screener (40 results).
• Hunt for overlooked opportunities before they hit the spotlight with the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com